Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Protein aggregates are emerging therapeutic targets in rare monogenic causes of cardiomyopathy and amyloid heart disease, but their role in more prevalent heart-failure syndromes remains mechanistically unexamined. We observed mislocalization of desmin and sarcomeric proteins to aggregates in human myocardium with ischemic cardiomyopathy and in mouse hearts with postmyocardial infarction ventricular remodeling, mimicking findings of autosomal-dominant cardiomyopathy induced by the R120G mutation

Myocardial Infarction 99

Myocardial Infarction Cardiomyopathy Heart Failure Heart Disease 99

Science Daily - Heart Disease

APRIL 2, 2025

When we move, it's harder for existing wearable devices to accurately track our heart activity. But researchers found that a starfish's five-arm shape helps solve this problem. Inspired by how a starfish flips itself over -- shrinking one of its arms and using the others in a coordinated motion to right itself -- scientists have created a starfish-shaped wearable device that tracks heart health in real time.

Heart Monitor 73

Heart Monitor Research 73

Physiologically Speaking

MARCH 30, 2025

This talk dives into the science of cardiovascular fitness, its profound impact on longevity, and how to train smarter without overcomplicating it. I delivered it at the Golden Age Health Summit on March 15, 2025, in Austin, TX. Key Takeaways: Why VO2 max is your longevity superpower How aerobic fitness declines with age—and what to do about it A simplified 3-zone training model: Easy (50-70% HR max), Moderate (70-85% HR max), and Hard (85-100% HR max) Practical tips to train effectively w

Physiology 104

Physiology BMI Cholesterol Risk Factors 104

American College of Cardiology

MARCH 30, 2025

Implantation of an intra-aortic balloon pump (IABP) did not improve 60-day survival or bridge to heart replacement (HRT) therapies in patients with heart failure-cardiogenic shock (HF-CS) compared to standard care, according to a study presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC. The trial was stopped by the Data Safety and Monitoring Board at the prespecified interim analysis due to futility.

Cardiogenic Shock 75

Cardiogenic Shock Heart Failure Aortic Outcomes 75

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Patient Care

Open Heart

MARCH 28, 2025

Background The significance of stress-test induced arrhythmias has been examined in prior studies, but there is no clear consensus regarding its significance. Objectives To determine the significance of stress test-induced arrhythmias. Methods Relevant studies examining arrhythmia in both exercise and pharmacological stress testing were searched for in PubMed, Embase and Cochrane databases from inception to 14 June 2023.

Arrhythmia 64

Arrhythmia Coronary Artery Disease Myocardial Infarction Atrial Fibrillation 64

Physiologically Speaking

MARCH 28, 2025

Greetings! Welcome to the Physiology Friday newsletter. Details about the sponsors of this newsletter including FSTFUEL electrolytes, Examine.com , and my book “VO2 Max Essentials ” can be found at the end of the post. You can find more products I’m affiliated with on my website. Physiologically Speaking is a reader-supported publication.

Exercise 71

Exercise Research Physiology Outcomes 71

American College of Cardiology

MARCH 29, 2025

The SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening heart failure (HF) in older adults with aortic stenosis undergoing TAVI, resulting in a 28% relative risk reduction, according to results from the DAPA-TAVI study presented during a Late-Breaking Clinical Trial session during ACC.25 in Chicago and simultaneously published in the NEJM.

Heart Failure 75

Heart Failure Stenosis Aortic Article 75

MIBHS

MARCH 31, 2025

When discussing heart health, heart attacks and cardiac arrest are two terms that are often mistaken for one another. While both are serious medical emergencies, they are not the same condition. Understanding the difference between heart attack and cardiac arrest can help in recognizing symptoms, seeking prompt medical care, and even saving lives. What is a Heart Attack?

Cardiac Arrest 52

Cardiac Arrest Heart Attack Heart attacks Chest Pain 52

DAIC

MARCH 28, 2025

tim.hodson Fri, 03/28/2025 - 15:23 Mar. 28, 2025 At theAmerican College of Cardiology (ACC) 2025 meeting,GE HealthCare will introduce RevolutionVibe, i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries.

Technology 59

Technology Coronary Artery Disease Atrial Fibrillation Medicare 59

CardiacWire

MARCH 29, 2025

Intravascular lithotripsy (IVL) may have once been synonymous with Shockwave Medical, but its now rapidly becoming one of the hottest segments in interventional cardiology, spurred on by Abbotts new IVL Investigational Device Exemption (IDE) from the FDA. IVL is a minimally invasive medical catheter-based procedure that treats calcified plaque in blood vessels.

Plaque 59

Plaque Interventional Cardiology Stents Stent 59

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Chimeric antigen receptor (CAR) T cell therapy shows promise for various diseases. Our studies in humanized mice and nonhuman primates demonstrate that hematopoietic stem cells (HSCs) modified with anti-HIV CAR achieve lifelong engraftment, providing functional antiviral CAR-T cells that reduce viral rebound after antiretroviral therapy (ART) withdrawal.

84

84

American College of Cardiology

MARCH 29, 2025

After stent implantation, a three-month regimen of dual antiplatelet therapy (DAPT) was more effective than a one-month regimen at reducing adverse events without increasing bleeding risk in patients with a high bleeding risk (HBR), according to a Late-Breaking Clinical Trial presented at ACC.25 in Chicago. Furthermore, in patients with a low bleeding risk (LBR), a three-month regimen was found to be superior to 12 months for reducing bleeding risk and comparable in reducing adverse events.

Stent 72

Stent Stents Article 72

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

BackgroundPostoperative blood glucose levels significantly impact outcomes in cardiac surgery patients undergoing extracorporeal circulation (ECC) auxiliary to open heart surgery. While hypoglycemia and hyperglycemia are known risk factors for adverse outcomes, the optimal glycemic range for patients undergoing ECC remains unclear. This research examined the relationship between blood glucose levels and 90-day mortality in this high-risk group.MethodsThe data for this research were obtained from

Open-Heart Surgery 52

Open-Heart Surgery Circulation ICU Outcomes 52

ECG Guru

MARCH 30, 2025

This is an interesting case for your students who want to delve into dysrhythmias with an eye on detail. It is also a good teaching case for discussing treatment options when the diagnosis may be uncertain or controversial. I will start the discussion by admitting that I am not an expert of electrophysiology or complex dysrhythmias. My approach has always been more clinical - how is this rhythm affecting the patient and what are the chances it will deteriorate?

Dysrhythmia 64

Dysrhythmia RN Chest Pain Electrophysiology 64

HCPLive

APRIL 1, 2025

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

COVID-19 143

COVID-19 143

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Lysyl hydroxylase 2 (LH2) is highly expressed in multiple tumor types and accelerates disease progression by hydroxylating lysine residues on fibrillar collagen telopeptides to generate stable collagen cross links in tumor stroma. Here, we show that a galactosylhydroxylysyl glucosyltransferase (GGT) domain on LH2-modified type-VI collagen (Col6) to promote lung adenocarcinoma (LUAD) growth and metastasis.

Cancer 59

Cancer Pharmacology 59

American College of Cardiology

MARCH 30, 2025

Clopidogrel monotherapy was found to be more effective than aspirin monotherapy in lowering risk of major adverse cardiac and cerebrovascular events among patients at high risk of recurrent ischemic events who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI, according to new research presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago and simultaneously published in The Lancet.

Research 65

Research Article 65

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

BackgroundPediatric cardiomyopathies are rare but life-threatening conditions with high mortality. Limited data exists on their clinical features and risk factors, especially in Asian populations, highlighting the need for further research in this area.MethodsThis retrospective cohort study analyzed data from 212 pediatric patients diagnosed with hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), or restrictive phenotype hypertrophic cardiomyopathy (RP-HCM) at a single center i

Risk Factors 52

Risk Factors Pediatrics Cardiomyopathy Pulmonary 52

ECG Guru

MARCH 30, 2025

This is an interesting case for your students who want to delve into dysrhythmias with an eye on detail. It is also a good teaching case for discussing treatment options when the diagnosis may be uncertain or controversial. I will start the discussion by admitting that I am not an expert of electrophysiology or complex dysrhythmias. My approach has always been more clinical - how is this rhythm affecting the patient and what are the chances it will deteriorate?

Dysrhythmia 64

Dysrhythmia RN Chest Pain Electrophysiology 64

HCPLive

MARCH 27, 2025

Panelists discuss how selecting among the numerous approved biologic therapies for psoriasis requires a personalized approach that weighs factors such as efficacy data, safety profiles, comorbidities, insurance coverage, and administration preferences, with patient preferences playing a crucial role in the decision-making process, as involving patients in treatment selection enhances medication adherence and satisfaction and ultimately improves long-term outcomes.

Outcomes 52

Outcomes 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Sleep disturbance is bidirectionally associated with an increased risk of Alzheimers disease and other tauopathies. While the sleep-wake cycle regulates interstitial and cerebrospinal fluid (CSF) tau levels, the underlying mechanisms remain unknown. Understanding these mechanisms is crucial, given the evidence that tau pathology spreads through neuron-to-neuron transfer, involving the secretion and internalization of pathological tau forms.

52

52

American College of Cardiology

MARCH 30, 2025

One of the most significant modifications that middle-aged patients can take to prevent cardiovascular disease is lowering arterial hypertension, according to research presented during a Featured Clinical Research Session at ACC.25 in Chicago and simultaneously published in NEJM. At 50 years of age, absence of uncontrolled hypertension and four other cardiovascular risk factors was associated with a decade-longer lifespan compared with the presence of all five.

Risk Factors 66

Risk Factors Hypertension Cardiovascular Disease Research 66

Frontiers in Cardiovascular Medicine

MARCH 28, 2025

ST-elevation myocardial infarction (STEMI) is a critical cardiovascular emergency characterized by acute coronary artery occlusion and subsequent myocardial injury. The current standard of care is primary percutaneous coronary intervention (PPCI), which aims to rapidly restore epicardial blood flow. However, despite successful revascularization, microvascular obstruction (MVO) remains a major challenge, contributing to adverse clinical outcomes.

Thrombolysis 52

Thrombolysis STEMI Myocardial Infarction Article 52

ADN Center of Excellence

MARCH 31, 2025

In the continuously evolving world of healthcare, keeping up with the latest findings, technologies, and best practices is vital for medical professionals. One of the most effective ways to do this is through conferences that focus on medical education. These events are not just a way to earn continuing education credits; they are foundational to shaping how healthcare providers learn and apply knowledge in their practices.

Best Practices 52

Best Practices Education Technology 52

Open Heart

MARCH 28, 2025

Background High-sensitivity cardiac troponin tests have enhanced early myocardial infarction diagnosis, yet many patients still land in the observe zone (OZ). Guidelines suggest a 3-hour troponin measurement for those in the European Society of Cardiology (ESC) 0/1 hour-algorithm’s OZ, but evidence on extended troponin testing times and their impact on diagnostic accuracy and outcomes remains sparse.

Myocardial Infarction 52

Myocardial Infarction Outcomes 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Mitochondrial dysfunction fuels vascular inflammation and atherosclerosis. Mitochondrial calcium uptake 1 (MICU1) maintains mitochondrial Ca2+ homeostasis. However, the role of MICU1 in vascular inflammation and atherosclerosis remains unknown. Here, we report that endothelial MICU1 prevents vascular inflammation and atherosclerosis by maintaining mitochondrial homeostasis.

Atherosclerosis 52

Atherosclerosis Coronary Artery Bypass Graft Coronary Artery Disease Plaque 52

American College of Cardiology

MARCH 31, 2025

Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or hospitalization for worsening pulmonary arterial hypertension (PAH) compared to placebo in high-risk adults with PAH, according to results from the ZENITH study presented during a Clinical and Investigative Horizons session at ACC.25 in Chicago and simultaneously published in NEJM.

Transplant 69

Transplant Outcomes Pulmonary Hypertension 69

Frontiers in Cardiovascular Medicine

MARCH 28, 2025

IntroductionHeart failure (HF) causes high symptom burden and shortens life expectancy. Implementation of Palliative Care (PC) concurrently with cardiologic guidelines-directed medical therapy (GDMT) improves quality-of-life (QoL) more than disease-oriented management alone but is underused. To facilitate provision of PC for people living with HF, the Swiss Society of Cardiology (SSC) and the Swiss Society for Palliative Care (palliative.ch) have created joint working-group.MethodsDyads represen

Quality of Life 52

Quality of Life Heart Failure Research Outcomes 52

Nature Reviews - Cardiology

MARCH 27, 2025

Nature Reviews Cardiology, Published online: 28 March 2025; doi:10.1038/s41569-025-01147-w Countries globally face major challenges in the early diagnosis and treatment of hypercholesterolaemia and cardiovascular disease, with numerous health inequities by geography and income. Perseverance, hard work, integrity and commitment can transform aspiration into reality.

Cardiovascular Disease 56

Cardiovascular Disease 56

DAIC

MARCH 31, 2025

tim.hodson Mon, 03/31/2025 - 10:26 March 31, 2025 AGEPHA Pharma USA, LLC, has released clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. The study, Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial, was presented at the American Col

Cardiovascular Disease 52

Cardiovascular Disease Plaque Coronary Artery Disease Heart Attack 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Neuroretinal degenerations including retinitis pigmentosa (RP) comprise a heterogeneous collection of pathogenic mutations that ultimately result in blindness. Despite recent advances in precision medicine, therapies for rarer mutations are hindered by burdensome developmental costs. To this end, Von Hippel-Lindau (VHL) is an attractive therapeutic target to treat RP.

Ablation 52

Ablation 52

American College of Cardiology

MARCH 30, 2025

PCI guided by a novel, artificial-intelligence-powered (AI) method of angiographic fractional flow reserve (FFR) assessment known as AngioFFR, which calculates FFR from a single-view angiogram of the coronary arteries, was noninferior to IVUS for outcomes in patients with significant stenosis, according to new research presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago and simultaneously published in the The Lancet.

Stenosis 63

Stenosis Research Outcomes Article 63

Frontiers in Cardiovascular Medicine

MARCH 28, 2025

BackgroundThere is a growing body of evidence indicating that metabolites are associated with an increased risk of cardiovascular diseases (CVDs), the underlying causality of these associations remains largely unchallenged. Given the inherent difficulty in establishing causality using epidemiological data, we employed the technique of Mendelian randomization to investigate the potential role of plasma metabolite factors in influencing the risk of CVDs.MethodsThe exposure was based on 1,400 plasm

Cardiovascular Disease 52

Cardiovascular Disease Atrial Fibrillation Aneurysm Heart Failure 52

Open Heart

MARCH 28, 2025

Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance patient safety.

Cardiomyopathy 52

Cardiomyopathy Biomarkers 52

DAIC

MARCH 27, 2025

tim.hodson Thu, 03/27/2025 - 12:18 March 27, 2025 Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System within Abbott's PFA clinical studies.

Ablation 52

Ablation AFIB Atrial Fibrillation Electrophysiology 52

HCPLive

MARCH 28, 2025

Experts discuss the long-term efficacy and safety of abrocitinib and upadacitinib in atopic dermatitis (AD), with sustained monotherapy results showing significant improvements in Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Validated IGA-AD (vIGA-AD) scores. They also consider the safety profiles and potential risks, particularly in older patients, for long-term use of JAK inhibitors.

52

52